What question did this study set out to answer?

This review aims to explore the role of PAI-1 in aging, its involvement in immunosenescence, and the potential of TM5614 as a therapeutic inhibitor.

May 27, 2026CellsOpen Access

Plasminogen Activator Inhibitor-1 as a Therapeutic Target for Healthy Longevity, Immunosenescence, and Age-Related Disease: Translational Development of the Small-Molecule Inhibitor TM5614

View Full Paper

Ask AI

Bookmark

This review aims to explore the role of PAI-1 in aging, its involvement in immunosenescence, and the potential of TM5614 as a therapeutic inhibitor.
Reviewed the biology and function of PAI-1 and its role in aging and immune dysregulation.
Summarized preclinical and clinical data on PAI-1 inhibitors, focusing on TM5614.
Discussed the translational opportunities and safety for TM5614 in various diseases.
TM5614 demonstrated potential anti-thrombotic, anti-fibrotic, anti-inflammatory, and anti-senescent effects.
Clinical evaluation included conditions like chronic myeloid leukemia and COVID-19 pneumonia.
PAI-1 is proposed as a key molecular node linking aging, cancer progression, and immune dysfunction.

No takes yet. Share an insight, caveat, or question.

Review highlights PAI-1 as a therapeutic target for aging and related diseases, indicating potential treatments through TM5614.

Abdelhakim et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark